Drug intelligence / Profile preview

ibuprofen + celecoxib

Development stage: Unknown
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral

Overview

The combination of ibuprofen and celecoxib represents concurrent use of two different NSAIDs. Ibuprofen is a non-selective COX inhibitor that blocks both COX-1 and COX-2 enzymes, while celecoxib (Celebrex) is a selective COX-2 inhibitor. Taking these medications together is generally not recommended due to increased risk of gastrointestinal side effects including bleeding, ulcers, and stomach irritation. This combination also increases the risk of cardiovascular events and kidney damage. Healthcare providers typically advise against using multiple NSAIDs simultaneously.

Brand names: CelebrexAdvilMotrin
Other names: ibuprofen and celecoxib

Targets

PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on ibuprofen + celecoxib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ibuprofen + celecoxib.

Explore the full profile